Corticosteroids, particularly dexamethasone, are one of the few drugs proven to reduce deaths from severe COVID-19. The benefit is specific and conditional: it applies to hospitalized patients who need supplemental oxygen or mechanical ventilation, not to people with mild symptoms managing the illness at home. This distinction matters because the same drug that saves lives in one context may cause harm in another, a pattern that took a massive clinical trial to pin down and that continues to shape how doctors treat COVID-19 today.
The Trial That Changed COVID Treatment
Before mid-2020, doctors were largely guessing about whether steroids helped or hurt COVID-19 patients. The turning point came from the RECOVERY trial in the United Kingdom, one of the largest randomized trials in the pandemic. Researchers assigned hospitalized COVID-19 patients to receive either dexamethasone (6 mg daily for up to ten days) or usual care alone. Among patients on invasive mechanical ventilation, the death rate dropped from about 41% with usual care to about 29% with dexamethasone. For patients receiving supplemental oxygen without a ventilator, mortality fell from roughly 26% to 23%. But for patients who were not receiving any respiratory support at the time they entered the trial, dexamethasone showed no benefit at all and even trended toward slightly higher mortality.
1PubMed. Dexamethasone in Hospitalized Patients with Covid-19That last finding is the one people often miss. Steroids are not a blanket treatment for COVID-19. They work when the body’s own inflammatory response has become the main threat, which happens in the sickest patients. In someone with a mild infection, suppressing the immune system with steroids removes a defense the body still needs.
A separate prospective cohort study of over 1,500 patients with severe and critical COVID-19 reinforced the RECOVERY trial’s message. Among patients on mechanical ventilation who received corticosteroids, the death rate was roughly half that of those who did not receive them. Overall, in-hospital mortality in the steroid-treated group was about 18% compared with 31% in the untreated group.
2PubMed Central. Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort studyHow Steroids Tame the Inflammatory Storm
Severe COVID-19 is, in many ways, an immune system problem. The virus triggers an exaggerated inflammatory response that can damage the lungs and other organs even after the viral load begins to drop. Key inflammatory molecules surge in the bloodstream, and that surge drives much of the tissue destruction that puts patients on ventilators.
Dexamethasone works by dialing down the production of these inflammatory signals. Modeling studies have shown that a 6 mg daily dose for ten days produces meaningful reductions in tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP), all markers that spike during severe COVID-19.
3PubMed Central. Anti-inflammatory effects of dexamethasone in COVID-19 patients: Translational population PK/PD modeling and simulationSimulations from that work indicated that doses below 6 mg were less effective at bringing down all three markers simultaneously, which helps explain why the 6 mg dose became the clinical standard.
This mechanism also explains the timing puzzle. Early in the illness, the immune response is doing useful work: attacking the virus. Suppressing it at that point can backfire, allowing the virus to replicate more freely. Later, when inflammation has spiraled out of control, tamping it down saves lives. The therapeutic window is narrow, and getting it right depends on where the patient is in the disease course.
Why Mild Cases Should Not Get Steroids
One persistent concern is that corticosteroids may delay how quickly the body clears the virus. This worry is not theoretical. Research has examined the influence of corticosteroid dose on the duration of viral shedding in COVID-19 patients, and the title of the key paper on the subject tells the story plainly: higher doses of corticosteroids appear to extend the period during which patients continue to shed virus.
4PubMed Central. Influence of Corticosteroid Dose on Viral Shedding Duration in Patients With COVID-19For a critically ill patient whose lungs are failing from inflammation, a somewhat longer period of viral shedding is an acceptable trade-off for survival. For someone with a cough and mild fever at home, it is not. This is the core reason that clinical guidelines consistently recommend against using systemic corticosteroids in outpatients with mild COVID-19. The RECOVERY trial’s own data, which showed a trend toward worse outcomes in hospitalized patients not needing oxygen, reinforced this point with hard numbers.
Does a Higher Dose Work Better?
Once the standard 6 mg daily dose of dexamethasone proved effective, a natural question followed: would doubling the dose save even more lives? The answer, based on the evidence available, is no.
A trial comparing high-dose dexamethasone to the standard dose in ICU patients with severe respiratory failure found no meaningful difference in 60-day mortality. About 26% of patients died in each group.
5JAMA Internal Medicine. High-Dose Dexamethasone and Oxygen Support Strategies in Intensive Care Unit Patients With Severe COVID-19 Acute Hypoxemic Respiratory FailureA separate analysis of mechanically ventilated patients reached the same conclusion, but with an important additional finding: high-dose dexamethasone was not just unhelpful, it was associated with higher average daily blood glucose levels and longer ICU stays. No benefit was seen in mortality, nosocomial infections, or ventilator-free days.
6Open Forum Infectious Diseases. 1124. Effect of High-Dose versus Standard-Dose Dexamethasone on Mortality Among Mechanically Ventilated COVID-19 PatientsThe bottom line on dosing is that more is not better. The standard 6 mg regimen remains the recommended approach, and escalating the dose introduces side effects without improving survival.
Dexamethasone Versus Other Steroids
Dexamethasone is not the only corticosteroid available. Methylprednisolone and hydrocortisone are common alternatives, and hospitals sometimes use whichever one they have on hand. A head-to-head trial comparing equivalent doses of all three in COVID-19-related acute respiratory distress syndrome found a trend favoring dexamethasone across several outcomes, including ventilator-free days, ICU length of stay, and 28-day mortality. Only the clinical status score at day 28 reached statistical significance, with dexamethasone patients scoring meaningfully better than those on methylprednisolone or hydrocortisone.
7PubMed Central. Comparison of the efficacy of equivalent doses of dexamethasone, methylprednisolone, and hydrocortisone for treatment of COVID-19-related acute respiratory distress syndromeThe trial was small, so the inability to reach statistical significance on other endpoints is not surprising. Still, most guidelines have kept dexamethasone as the first-choice steroid for COVID-19, with methylprednisolone or hydrocortisone as acceptable substitutes when dexamethasone is unavailable. A study from the Omicron wave era also noted that the specific type of corticosteroid used did not significantly affect overall outcomes, suggesting the anti-inflammatory class effect matters more than the individual drug when adjusted for potency.
8PubMed Central. Impact of corticosteroid doses on prognosis of severe and critical COVID-19 patients with Omicron variant infectionInhaled Steroids for People Not Sick Enough to Be Hospitalized
Systemic steroids like dexamethasone pills or injections are reserved for seriously ill patients. But what about inhaled corticosteroids, the kind people with asthma use daily? These deliver the drug directly to the airways with far less effect on the rest of the body, and researchers wondered if they could help people with COVID-19 recover faster at home.
The UK’s PRINCIPLE trial tested inhaled budesonide in community-dwelling adults at higher risk of complications. Patients who used the inhaler recovered about three days faster on average than those who received usual care alone, with a median time to self-reported recovery of roughly 12 days versus nearly 15 days.
9PubMed Central. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE)A living meta-analysis that pooled results from multiple trials found that inhaled corticosteroids improved clinical recovery at both 7 and 14 days. However, the benefit was not equal across all drugs: budesonide showed significant efficacy, while ciclesonide, a different inhaled steroid, did not.
10PubMed Central. Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: A living review and meta-analysisInhaled steroids are not a dramatic life-saver in the same way that dexamethasone is for ventilated patients. They shave days off recovery and may reduce the risk of progressing to hospitalization, which is still a meaningful benefit for outpatients. They did not, however, become universally adopted into guidelines. Many treatment protocols mention inhaled budesonide as a reasonable option for high-risk outpatients, rather than a strong recommendation.
Combining Steroids with Other Drugs
Corticosteroids became the foundation of inpatient COVID-19 treatment, but they are often used alongside other medications. The most studied combination is dexamethasone with tocilizumab, an interleukin-6 receptor blocker that targets the same inflammatory pathway from a different angle.
A randomized trial from the CORIMUNO-19 group compared tocilizumab plus dexamethasone to dexamethasone alone in patients with moderate-to-severe COVID-19 pneumonia. At day 14, the combined treatment showed a trend toward fewer patients needing invasive ventilation or dying, though the result did not cross the threshold for strong statistical certainty. Where the combination did clearly shine was in speed of improvement: patients on the two-drug regimen were more likely to be off supplemental oxygen by day 28 (about 82% versus 72%) and more likely to be discharged (about 83% versus 73%).
11eClinicalMedicine. Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumoniaBaricitinib, a different immune-modulating drug, has also been used alongside steroids. One retrospective comparison from a New York City hospital system found no clear mortality difference between patients who received tocilizumab and those who received baricitinib when both were used on top of standard care including corticosteroids.
12Open Forum Infectious Diseases. Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19The current treatment landscape for hospitalized patients often involves dexamethasone as the base layer, with tocilizumab or baricitinib added for patients who are deteriorating or who have high inflammatory markers. This layered approach has become standard of care in many hospital systems.
13PubMed Central. COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological ConsiderationsRisks and Side Effects of Steroid Use in COVID-19
Corticosteroids are not gentle drugs. Even a 10-day course of dexamethasone carries real risks, and those risks grow with higher doses or longer durations. The most common concern during treatment is elevated blood sugar. COVID-19 itself can raise glucose levels, and layering steroids on top amplifies this problem. In one study, 60% of hospitalized COVID-19 patients had elevated blood glucose, and those with higher glucose also had higher cortisol and markers of inflammation.
14medRxiv. Elevated Blood Glucose in COVID-19 Patients: An explorative StudyFor patients who already have diabetes, this glucose spike can be dangerous and requires careful insulin management during steroid treatment. The high-dose dexamethasone studies mentioned earlier specifically flagged significantly higher blood glucose in the high-dose group as a measurable harm.
Psychiatric effects are another known risk. Case reports have documented acute psychosis developing within days of starting intravenous methylprednisolone for COVID-19. Steroid-induced psychiatric effects can include agitation, mania, anxiety, delirium, and frank psychosis, and they sometimes appear in patients with no prior psychiatric history.
15European Psychiatry. Acute psychosis following corticosteroid administration for COVID-19 and Respiratory Syncytial Virus infection: A case studyThe Mucormycosis Crisis
One of the most alarming complications linked to steroid use during the pandemic was a surge of mucormycosis, a rare but devastating fungal infection sometimes called “black fungus.” During India’s devastating Delta wave, thousands of COVID-19 survivors developed mucormycosis, and the pattern was striking: most of these patients had diabetes and had received steroids during their COVID-19 treatment.
16PubMed Central. Mucormycosis: An opportunistic pathogen during COVID-19The combination of poorly controlled diabetes, corticosteroid-driven immune suppression, and possibly overuse of antibiotics creates an environment where fungal pathogens can take hold. Mucormycosis invades blood vessels, causing tissue death, and often requires radical surgery along with antifungal therapy. The infections hit the sinuses, orbits, and brain in many cases, and mortality rates were high.
17Current Treatment Options in Allergy. Prevention and Treatment of COVID-19-Associated MucormycosisThe mucormycosis wave was not caused by appropriate steroid use in ICU patients. It was driven largely by the overuse and prolonged use of corticosteroids in patients who may not have needed them, particularly in settings where access to care was strained and steroids were sometimes given outside of hospital settings to patients with mild disease. The lesson is not that steroids should be avoided in severe COVID-19, but that they must be used carefully and not handed out indiscriminately.
Steroids in Children with COVID-Related Inflammation
Children rarely develop severe acute COVID-19 in the same way adults do, but a subset develops Multisystem Inflammatory Syndrome in Children (MIS-C) weeks after their initial infection. MIS-C involves fever, widespread inflammation, and dysfunction across multiple organ systems, and it can be life-threatening. The American College of Rheumatology has issued clinical guidance recommending corticosteroids as part of the treatment approach for MIS-C, alongside other immunomodulatory therapies.
18PubMed Central. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3MIS-C is fundamentally an inflammatory condition rather than an active viral infection by the time it appears, which means the rationale for steroids tracks with the adult evidence: when the problem is the immune system’s overreaction rather than the virus itself, dampening that response helps.
How Newer Variants Changed the Picture
Most of the pivotal steroid trials were conducted during the original and Alpha waves of SARS-CoV-2. A reasonable question is whether the same treatment still applies as the virus has evolved through Delta, Omicron, and subsequent subvariants.
Omicron-era studies have continued to examine corticosteroid use in severe and critical patients. A retrospective study from Chongqing, China acknowledged that the efficacy of corticosteroid treatment during the Omicron outbreak had not been well reported, but the drug remained recommended for severe cases.
19Scientific Reports. Corticosteroids for hospitalized patients with severe/critical COVID-19: a retrospective study in Chongqing, ChinaOne complicating factor is that Omicron and its descendants tend to cause less severe lung disease than earlier variants, at least in vaccinated populations. Fewer patients end up on ventilators, which means fewer patients reach the threshold where steroids provide their greatest benefit. The drug has not stopped working; the disease presentation has shifted so that a smaller fraction of infected people need it. For those who do develop severe illness requiring oxygen or ventilatory support, corticosteroids remain part of the standard treatment toolkit.
Why the Medical Community Was Initially Skeptical
Before the RECOVERY trial results, many experts were actively warning against using steroids for COVID-19. This caution was rooted in experience with earlier coronavirus outbreaks. During SARS in 2003 and MERS beginning in 2012, corticosteroids were used in some patients, but no randomized trials were conducted. A systematic review noted that the WHO and CDC had refrained from recommending routine corticosteroid use, and prominent researchers explicitly argued that steroids could be harmful.
20PubMed Central. Efficacy of Corticosteroids in Patients with SARS, MERS and COVID-19: A Systematic Review and Meta-AnalysisThe concern was well-founded based on the data available at the time. Observational studies from SARS and MERS had produced mixed results, and some suggested that steroids delayed viral clearance and increased complications without a clear mortality benefit. It took the rigorous, large-scale design of the RECOVERY trial to separate the signal from the noise and show that timing and severity were the critical variables. The lesson is worth remembering: even a drug as familiar as dexamethasone needed a proper trial to define when it helps and when it hurts. Prior coronavirus experience alone was not enough to settle the question.